Breaking News

WuXi PharmaTech Appoints Ops SVP

By Kristin Brooks | February 27, 2014

Mu to head product development service and partnership business unit

Dr. Hua Mu has been appointed senior vice president of operations and global head of the product development service and partnership business unit at WuXi PharmaTech. Dr. Mu reports to Dr. Ge Li, chairman and chief executive officer.
 
Dr. Mu has more than 18 years of clinical research and development experience, having held medical and clinical leadership positions with Roche, Abraxis Bioscience (now Celgene), Biogen Idec, Genentech, and Procter and Gamble. Dr. Mu's experience includes early- to late-stage development of cytotoxic agents, small molecules, and monoclonal antibodies; management of clinical and regulatory organizations, oversight of external collaborations and partnerships, interaction with regulatory authorities in the U.S., Europe and Asia; and advancement of drug candidates to market and post-market development.
 
Dr. Mu joins the company from Hutchison MediPharma, where he served as executive vice president and chief medical officer. During his tenure, the company successfully obtained five IND approvals and one Phase II/III CTA approval from the China Food and Drug Administration, and advanced six compounds into clinical development.
 
"I am delighted to welcome Hua to WuXi's leadership team," said Dr. Li. "Hua brings extensive experience, particularly in clinical development in China, that is very critical for WuXi to help our partners bring their innovations to China and to develop innovative drugs to benefit Chinese patients."

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent